OMTO, Volume *13*

Supplemental Information

Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells

Lei Wang, Jianfang Ning, Hiroaki Wakimoto, Shulin Wu, Chin-lee Wu, Melissa R. Humphrey, Samuel D. Rabkin, and Robert L. Martuza

SUPPLEMENTARY FIGURE LEGENDS

Supplementary Fig. 1. PCSCs are sensitive to G47Δ in the absence of heparin. (A) G47Δ-mCherry infection of DU145 PCSCs with and without heparin and imaged at different times post-infection (24h, 48h and 72h). Experimental conditions: 4×10^4 DU145 PCSCs/well of 6-well plate. G47Δ-mCherry = 1 MOI. (B) Dose response curve for G47Δ in DU145 PCSCs in the presence of heparin at day 4, under semi-heparin conditions at day 4 (C), and with semi-heparin or without heparin at day 6 (D). For semi heparin condition, PCSCs were infected in EF20 medium without heparin for 2 hr then normal EF20 medium added.

Supplementary Fig 2. PCSC susceptibility to oHSV killing. (A) oHSV (G47Δ and MG18L) dose response curves in DU145 PCSCs. (B) oHSV dose response curves in TRAMP-C2 PCSCs.

Supplementary Fig. 3. oHSV combined with chemotherapy, radiotherapy, NOTCH or Wnt inhibitors is not more effective. (A) Docetaxel (Doc; upper) or cisplatin (DDP; lower) dose response curves in combination with oHSVs (G47Δ and MG18L; MOIs indicated in each panel) in PCSCs. (B) PCSC viability after G47Δ (MOI=0.3) combined with radiotherapy (Dose (Gy) indicated). (C) oHSVs combined with Wnt inhibitor (ICG001) in PCSCs. (D) oHSVs combined with NOTCH inhibitor (GSI) in PCSCs. Cell viability measured by MTS assay at 6 days.

Supplementary Fig. 4. Lack of toxicity associated with therapy. (A) H&E staining of heart, liver, spleen, kidney and lung of mice in each group. Bar indicates 100 μm. (B) Weight of individual mice in each group.

Supplementary Figure 1.



Supplementary Figure 2.



Supplementary Figure 3.



Supplementary Figure 4.